

BIOGEN IDEC INC  
Form 8-K  
November 30, 2004

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **November 23, 2004**

**Biogen Idec Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**0-19311**  
(Commission  
File Number)

**33-0112644**  
(I.R.S. Employer  
Identification No.)

**14 Cambridge Center, Cambridge, Massachusetts**  
(Address of principal executive offices)

**02142**  
(Zip Code)

Registrant's telephone number, including area code: **(617) 679-2000**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**TABLE OF CONTENTS**

Item 8.01 Other Events

Item 9.01 Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

Ex-99.1 Press Release dated November 23, 2004

---

**Table of Contents**

**Item 8.01 Other Events**

On November 23, 2004, the Registrant publicly disseminated a press release announcing the approval of TYSABRI® (natalizumab), formerly referred to as ANTEGREN®, as a treatment for relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses. The FDA granted accelerated approval for TYSABRI following priority review based on one-year data from two Phase III clinical studies, the AFFIRM monotherapy trial and the SENTINEL combination trial with AVONEX® (Interferon beta-1a). The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto.

**Item 9.01 Financial Statements and Exhibits**

(c) Exhibits.

99.1 The Registrant's Press Release dated November 23, 2004.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Biogen Idec Inc.**

By: /s/ Anne Marie Cook

---

Anne Marie Cook  
Vice President, Chief Corporate Counsel

Date: November 30, 2004

---

**Table of Contents**

**EXHIBIT INDEX**

| <b>Exhibit Number</b> | <b>Description</b>                                     |
|-----------------------|--|
| 99.1                  | The Registrant's Press Release dated November 23, 2004 |